Stocks Health care VVOS
NASDAQ · Health careVivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. brought in $20.9M of revenue over the twelve months to June 30, 2026, up 45.2% from a year earlier. It posted a net loss of $25.5M. In fiscal 2025 capital spending exceeded operating cash flow by $17.6M. At June 30, 2026 it held $1.8M in cash against $582K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Vivos Therapeutics, Inc.
- Net worth
- Vivos Therapeutics, Inc. has a market value (market cap) of $1.7M at the latest share price, and shareholders' equity of -$3.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $17.4M (+16.0% year on year), with a net loss of $21.2M. Over the 12 months to June 30, 2026: revenue $20.9M, net loss $25.5M.
- Cash flow
- In fiscal 2025 operations used $15.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Vivos Therapeutics, Inc. does
Vivos Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker VVOS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $17.4M | -$21.2M | -$2.07 | -$17.6M |
| 2024 | $15M | -$11.1M | -$2.22 | -$13.3M |
| 2023 | $13.8M | -$13.6M | -$11.14 | -$12.7M |
| 2022 | $16M | -$23.8M | -$25.90 | -$20.5M |
| 2021 | $16.9M | -$20.3M | -$0.96 | -$18.1M |
| 2020 | $13.1M | -$12.1M | -$1.40 | -$5.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VVOS ranks in Health care
Latest SEC filings
What Vivos Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Auditor change 8-K
- September 8, 2026Material agreement 8-K/A
- September 8, 2026
- September 3, 2026Passive stake changed SCHEDULE 13G/A
- August 21, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 35% to $5.2M versus the same quarter last year; diluted EPS -$0.31 versus -$0.55.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026Passive stake (5% or more) SCHEDULE 13G
- August 3, 2026
Insider trades
What the people running Vivos Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 31, 2026 | Amman Bradford K.Principal Accounting Officer | Received as pay | 250,000 | $102.5K |
| June 30, 2026 | Huntsman Ronald KirkChief Executive Officer, Director | Other changeindirect | 85,910 | $50K |
| March 31, 2026 | Skaff Michael C10% owner | Boughtindirect | 1,044,777 | $1.4M |
| March 31, 2026 | Skaff Michael C10% owner | Boughtindirect | 308,848 | $413.9K |
Who owns VVOS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| SP Manager LLC13D, may seek influence with 5 related filers | 19.9% | July 15, 2026 |
| Dawei Luo13G, passive | 8.52% | July 14, 2025 |
Largest institutional holders
Insiders
3 insiders reported holding 1,689,615 shares in total, about $145.8K at the last price.
| Holder | Shares |
|---|---|
| Skaff Michael C10% owner | 1,353,6251,353,625 held indirectly |
| Amman Bradford K.Principal Accounting Officer | 250,080 |
| Huntsman Ronald KirkChief Executive Officer, Director | 85,91085,910 held indirectly |
Questions about VVOS
What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as VVOS. Its shares trade on NASDAQ under the ticker VVOS.
What is Vivos Therapeutics, Inc.'s net worth?
Vivos Therapeutics, Inc. has a market value (market cap) of $1.7M at the latest share price, and shareholders' equity of -$3.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Vivos Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $25.5M on revenue of $20.9M.
How much revenue does Vivos Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Vivos Therapeutics, Inc. reported revenue of $20.9M. That is 45.2% more than a year earlier.
When did Vivos Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the auditor change from October 1, 2026.
Similar companies
Compare VVOS with
Follow VVOS
Get an email when Vivos Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Vivos Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.